Sarepta Therapeutics, Inc. (SRPT) Stock Analysis and Metrics

Sarepta Therapeutics

NASDAQ: SRPT

$15.67 ▼ -0.21 (-1.32%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.66 Bn

P/E25.47

P/S0.76

Div. Yield0.00

ROIC (Qtr)-0.03

Total Debt (Qtr)838.16 Mn

Revenue Growth (1y) (Qtr)448.10

Add ratio to table…

About

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic modalities for the treatment of rare diseases. The company's primary emphasis is on Duchenne muscular dystrophy, for which it has commercialized four products, and it also advances programs in facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, spinocerebellar ataxia, idiopathic pulmonary fibrosis and Huntington's disease.

Revenue is generated principally from the sale of its approved Duchenne therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45 and the gene therapy ELEVIDYS. Product sales to patients, hospitals and specialty pharmacy providers accounted for net revenues of $1,864.3 million in 2025, $1,788.0 million in 2024 and $1,144.9 million in 2023. The company also earns royalties and milestone payments from collaboration partners, although product sales constitute the core of its revenue stream.

Sarepta Therapeutics, Inc. holds a leading position in the Duchenne muscular dystrophy market as the developer of the first FDA-approved exon-skipping therapies and the first gene therapy, ELEVIDYS, for this indication. Its competitors include Nippon Shinyaku with its exon 53 skipping drug VILTEPSO, Italfarmaco with the steroid Givinostat, and several biotech firms pursuing alternative exon-skipping, gene editing and siRNA approaches. Competitive advantages stem from its proprietary phosphorodiamidate morpholino chemistry, the Arrowhead siRNA platform, the AAVrh.74 vector used in its gene therapy candidates, and a portfolio of orphan drug and regulatory exclusivities that protect its marketed products.

The company serves patients diagnosed with Duchenne and other rare neuromuscular disorders, delivering its therapies through hospitals, outpatient infusion centers and a limited network of home infusion specialty pharmacy providers in the United States. Outside the U. S., distribution occurs via third-party distributors and service providers under expanded access programs or in countries where its products have received marketing approval. Specific customer names are not disclosed in the filing.

Investment Thesis

▲ Bull case

Sarepta Therapeutics' siRNA pipeline, particularly SRP-1001 for FSHD and SRP-1003 for DM1, represents a significant hidden catalyst that the market is underestimating due to management's restrained emphasis during the earnings call despite compelling early data. The Phase 1/2 data shows dose-dependent increases in plasma exposure, superior targeted muscle delivery via alpha v beta 6 integrin targeting over transferrin receptor approaches, and robust target gene suppression without dose-limiting toxicity, which directly addresses historical delivery challenges in siRNA therapeutics. This differentiation is critical because FSHD and DM1 are high-unmet-need areas with no approved disease-modifying therapies, and Sarepta's approach enables deeper tissue penetration—such as striatal delivery in Huntington's disease programs—potentially overcoming blood-brain barrier limitations that have hindered competitors. The company is fully funding these programs internally through its strong cash position of $748 million and positive base business cash flow, eliminating dilution risk and allowing uninterrupted advancement toward registrational milestones. With MAD cohort data and early functional outcomes expected later in 2026, positive readouts could trigger accelerated partnership interest or standalone valuation uplift, especially as management noted they are already defining optimal registrational pathways with the FDA post-Phase 2. The market's focus on near-term Alevitus stabilization overlooks this long-term value engine, where success in even one siRNA program could redefine Sarepta's growth trajectory beyond its Duchenne franchise, supported by preclinical evidence showing correlation between target knockdown and functional improvement in DM1 and DUX4 suppression linked to clinical benefit in FSHD.
The commercial expansion initiatives for Alevitus, including the more-than-doubled sales force and deployed contract team, are creating a sustainable growth foundation that the market is prematurely dismissing due to the six-month lag between enrollment and infusion, which obscures near-term revenue visibility. Patrick Moss explicitly stated that enrollment form activity is now more geographically diverse, with previously inactive sites from 2025 re-engaging and submitting forms, signaling renewed physician confidence and broadening referral ecosystem traction. This foundational work—supported by educational efforts integrating three-year EMBARK data and muscle MRI evidence—is addressing the core information gap around Alevitus' disease-modifying impact, which management emphasized is grounded in evidence from over 1,300 treated patients showing preserved muscle trajectory and reduced fat/fibrotic replacement. Crucially, the company is not chasing sharp inflection but building steady momentum through repetition and reach, with visibility into improvement expected to emerge progressively through latter 2026 and into 2027, aligning with their cautioned guidance stance. The Alevitus franchise benefits from structural durability as the only FDA-approved gene therapy for ambulatory Duchenne, with high adherence in the PMO franchise creating cross-selling opportunities and a well-understood safety profile that supports physician confidence. With base business cash flow remaining positive excluding Arrowhead payments and operating leverage evident in the 82% gross margin on unit sales, incremental Aevitus growth will flow directly to profitability, and the resumption of non-ambulatory access via Cohort 8 could unlock a significant additional patient population if sirolimus pretreatment successfully mitigates acute liver injury as interim real-world data suggests.
The ongoing regulatory strategy for transitioning AMONDYS 45 and VYONDYS 53 to traditional approval via sNDAs represents an underappreciated de-risking catalyst that strengthens the long-term viability of Sarepta's PMO franchise, which contributed $229 million in Q1 net product revenue. Management confirmed the sNDAs were submitted in April with a regular review timeline and anticipated PDUFA date in February, avoiding the uncertainty of priority review delays while leveraging robust real-world evidence from the ESSENCE confirmatory study and published data supporting clinical benefit in survival and cardiac function. This move is critical because traditional approval transforms these therapies from contingent accelerated approvals into durable, label-stable products with reduced regulatory overhang, making them less vulnerable to future confirmatory trial failures and more attractive to payers and physicians seeking long-term treatment certainty. The franchise already demonstrates exceptional adherence rates and is viewed by physicians as foundational for slowing Duchenne decline, particularly for patients ineligible for or choosing to defer gene therapy. By securing traditional approval, Sarepta eliminates a key investor concern about the franchise's longevity, thereby stabilizing a reliable cash flow base that can continue to fund pipeline innovation without reliance on volatile gene therapy uptake cycles. The market's focus on Alevitus volatility overlooks this quiet but vital de-risking of the PMO business, which provides structural resilience and predictability to the overall revenue profile, especially as commercial expansion efforts for Alevitus mature over the next 12–18 months.

Sarepta Therapeutics' siRNA pipeline, particularly SRP-1001 for FSHD and SRP-1003 for DM1, represents a significant hidden catalyst that the market is underestimating due to management's restrained emphasis during the earnings call despite compelling early data. The Phase 1/2 data shows dose-dependent increases in plasma exposure, superior targeted muscle delivery via alpha v beta 6 integrin targeting over transferrin receptor approaches, and robust target gene suppression without dose-limiting toxicity, which directly addresses historical delivery challenges in siRNA therapeutics. This differentiation is critical because FSHD and DM1 are high-unmet-need areas with no approved disease-modifying therapies, and Sarepta's approach enables deeper tissue penetration—such as striatal delivery in Huntington's disease programs—potentially overcoming blood-brain barrier limitations that have hindered competitors. The company is fully funding these programs internally through its strong cash position of $748 million and positive base business cash flow, eliminating dilution risk and allowing uninterrupted advancement toward registrational milestones. With MAD cohort data and early functional outcomes expected later in 2026, positive readouts could trigger accelerated partnership interest or standalone valuation uplift, especially as management noted they are already defining optimal registrational pathways with the FDA post-Phase 2. The market's focus on near-term Alevitus stabilization overlooks this long-term value engine, where success in even one siRNA program could redefine Sarepta's growth trajectory beyond its Duchenne franchise, supported by preclinical evidence showing correlation between target knockdown and functional improvement in DM1 and DUX4 suppression linked to clinical benefit in FSHD.
The commercial expansion initiatives for Alevitus, including the more-than-doubled sales force and deployed contract team, are creating a sustainable growth foundation that the market is prematurely dismissing due to the six-month lag between enrollment and infusion, which obscures near-term revenue visibility. Patrick Moss explicitly stated that enrollment form activity is now more geographically diverse, with previously inactive sites from 2025 re-engaging and submitting forms, signaling renewed physician confidence and broadening referral ecosystem traction. This foundational work—supported by educational efforts integrating three-year EMBARK data and muscle MRI evidence—is addressing the core information gap around Alevitus' disease-modifying impact, which management emphasized is grounded in evidence from over 1,300 treated patients showing preserved muscle trajectory and reduced fat/fibrotic replacement. Crucially, the company is not chasing sharp inflection but building steady momentum through repetition and reach, with visibility into improvement expected to emerge progressively through latter 2026 and into 2027, aligning with their cautioned guidance stance. The Alevitus franchise benefits from structural durability as the only FDA-approved gene therapy for ambulatory Duchenne, with high adherence in the PMO franchise creating cross-selling opportunities and a well-understood safety profile that supports physician confidence. With base business cash flow remaining positive excluding Arrowhead payments and operating leverage evident in the 82% gross margin on unit sales, incremental Aevitus growth will flow directly to profitability, and the resumption of non-ambulatory access via Cohort 8 could unlock a significant additional patient population if sirolimus pretreatment successfully mitigates acute liver injury as interim real-world data suggests.
The ongoing regulatory strategy for transitioning AMONDYS 45 and VYONDYS 53 to traditional approval via sNDAs represents an underappreciated de-risking catalyst that strengthens the long-term viability of Sarepta's PMO franchise, which contributed $229 million in Q1 net product revenue. Management confirmed the sNDAs were submitted in April with a regular review timeline and anticipated PDUFA date in February, avoiding the uncertainty of priority review delays while leveraging robust real-world evidence from the ESSENCE confirmatory study and published data supporting clinical benefit in survival and cardiac function. This move is critical because traditional approval transforms these therapies from contingent accelerated approvals into durable, label-stable products with reduced regulatory overhang, making them less vulnerable to future confirmatory trial failures and more attractive to payers and physicians seeking long-term treatment certainty. The franchise already demonstrates exceptional adherence rates and is viewed by physicians as foundational for slowing Duchenne decline, particularly for patients ineligible for or choosing to defer gene therapy. By securing traditional approval, Sarepta eliminates a key investor concern about the franchise's longevity, thereby stabilizing a reliable cash flow base that can continue to fund pipeline innovation without reliance on volatile gene therapy uptake cycles. The market's focus on Alevitus volatility overlooks this quiet but vital de-risking of the PMO business, which provides structural resilience and predictability to the overall revenue profile, especially as commercial expansion efforts for Alevitus mature over the next 12–18 months.

▼ Bear case

Sarepta Therapeutics faces significant near-term execution risks in commercializing Alevitus that the market may be underpricing, particularly the persistent information gap and safety misperceptions that continue to suppress demand despite expanded commercial initiatives. While Patrick Moss noted increased HCP engagement and geographic diversity in enrollment forms, the fundamental challenge remains that Alevitus is a one-time therapy with a six-month enrollment-to-infusion cycle, making quarterly revenue highly sensitive to transient factors like illness or seasonal fluctuations—as highlighted by Douglas Ingram's comment that 'a couple of patients catching the flu' can impact results. This structural volatility is compounded by the lingering negative perception from 2025 events that distracted from Alevitus' efficacy, requiring sustained educational efforts to overcome entrenched safety concerns around acute liver injury, even as Cohort 8 data remains pending. The company's own guidance cautions against raising estimates prematurely, signaling management's lack of confidence in near-term inflection, and the reliance on qualitative feedback like 'green shoots' without concrete leading indicators such as accelerating enrollment form conversion rates or declining sales cycle times introduces uncertainty. Without clear, quantifiable improvements in patient conversion metrics, the current commercial expansion—while well-intentioned—risks becoming a costly overhead burden if it fails to translate into sustained demand growth, especially given the high fixed costs associated with maintaining an expanded sales force and contract team amid only modest base business cash flow positivity excluding Arrowhead-related outflows.
The siRNA pipeline, while scientifically promising, carries substantial binary clinical and regulatory risks that the market may be overlooking due to early-phase enthusiasm, particularly given the historical difficulties in translating target engagement to meaningful functional outcomes in neurodegenerative and muscular dystrophy indications. Louise Rodino-Klapac acknowledged that significant movement in functional measures is not expected at six-month follow-up in FSHD, and in DM1, definitive conclusions on timed function tests remain premature due to early disease state and cohort size limitations, meaning the upcoming MAD data will primarily inform dose selection rather than provide efficacy proof. This creates a scenario where positive biomarker data (e.g., DMPK knockdown, DUX4 suppression) could fail to translate into clinical benefit, mirroring past industry failures where siRNA therapies achieved target modulation but missed functional endpoints in Phase 3 trials. Furthermore, the company's plan to discuss registrational pathways with the FDA post-Phase 2 does not guarantee alignment, especially if the agency requires larger or longer trials than anticipated, potentially delaying timelines and increasing costs. With Sarepta fully funding these programs internally, any clinical setback would directly impact cash reserves without the option to seek external financing gracefully, and the opportunity cost of capital allocated to siRNA could hinder investment in more near-term commercial levers for Alevitus growth, creating a strategic misallocation risk if pipeline optimism outweighs near-term execution realities.
The resumption of Alevitus for non-ambulatory patients via Cohort 8 and sirolimus pretreatment remains speculative and faces significant hurdles that the market may be ignoring, despite management's optimistic framing of interim real-world evidence showing no liver enzyme elevations to date. James Richardson explicitly differentiated between clinical trial and real-world ALI incidence, noting that the research assay GLDH used in Cohort 8 may not reflect real-world sensitivity, and the open-label design allows for sample size adjustments if deviations arise—introducing potential variability in trial interpretation. Even if Cohort 8 succeeds, securing FDA concurrence to resume non-ambulatory dosing is not guaranteed, as the agency may require additional safety data or impose restrictive conditions given the history of acute serious liver injury and fatal acute liver failure associated with Alevitus, which carries a boxed warning. Furthermore, the non-ambulatory population represents a smaller, more complex subset of Duchenne patients with higher comorbidities, potentially limiting addressable market size and slowing adoption even if approved. The company's own Phase 4 ENHANCE study, which James Richardson described as 'not part of a broader regulatory strategy,' suggests internal recognition that real-world evidence alone may not suffice for regulatory approval, adding uncertainty to the timeline and likelihood of successfully reopening this indication. Without a clear, near-term path to non-ambulatory access, Sarepta misses a meaningful growth lever, leaving growth overly dependent on the slower, education-driven recovery in the ambulatory population.

Sarepta Therapeutics faces significant near-term execution risks in commercializing Alevitus that the market may be underpricing, particularly the persistent information gap and safety misperceptions that continue to suppress demand despite expanded commercial initiatives. While Patrick Moss noted increased HCP engagement and geographic diversity in enrollment forms, the fundamental challenge remains that Alevitus is a one-time therapy with a six-month enrollment-to-infusion cycle, making quarterly revenue highly sensitive to transient factors like illness or seasonal fluctuations—as highlighted by Douglas Ingram's comment that 'a couple of patients catching the flu' can impact results. This structural volatility is compounded by the lingering negative perception from 2025 events that distracted from Alevitus' efficacy, requiring sustained educational efforts to overcome entrenched safety concerns around acute liver injury, even as Cohort 8 data remains pending. The company's own guidance cautions against raising estimates prematurely, signaling management's lack of confidence in near-term inflection, and the reliance on qualitative feedback like 'green shoots' without concrete leading indicators such as accelerating enrollment form conversion rates or declining sales cycle times introduces uncertainty. Without clear, quantifiable improvements in patient conversion metrics, the current commercial expansion—while well-intentioned—risks becoming a costly overhead burden if it fails to translate into sustained demand growth, especially given the high fixed costs associated with maintaining an expanded sales force and contract team amid only modest base business cash flow positivity excluding Arrowhead-related outflows.
The siRNA pipeline, while scientifically promising, carries substantial binary clinical and regulatory risks that the market may be overlooking due to early-phase enthusiasm, particularly given the historical difficulties in translating target engagement to meaningful functional outcomes in neurodegenerative and muscular dystrophy indications. Louise Rodino-Klapac acknowledged that significant movement in functional measures is not expected at six-month follow-up in FSHD, and in DM1, definitive conclusions on timed function tests remain premature due to early disease state and cohort size limitations, meaning the upcoming MAD data will primarily inform dose selection rather than provide efficacy proof. This creates a scenario where positive biomarker data (e.g., DMPK knockdown, DUX4 suppression) could fail to translate into clinical benefit, mirroring past industry failures where siRNA therapies achieved target modulation but missed functional endpoints in Phase 3 trials. Furthermore, the company's plan to discuss registrational pathways with the FDA post-Phase 2 does not guarantee alignment, especially if the agency requires larger or longer trials than anticipated, potentially delaying timelines and increasing costs. With Sarepta fully funding these programs internally, any clinical setback would directly impact cash reserves without the option to seek external financing gracefully, and the opportunity cost of capital allocated to siRNA could hinder investment in more near-term commercial levers for Alevitus growth, creating a strategic misallocation risk if pipeline optimism outweighs near-term execution realities.
The resumption of Alevitus for non-ambulatory patients via Cohort 8 and sirolimus pretreatment remains speculative and faces significant hurdles that the market may be ignoring, despite management's optimistic framing of interim real-world evidence showing no liver enzyme elevations to date. James Richardson explicitly differentiated between clinical trial and real-world ALI incidence, noting that the research assay GLDH used in Cohort 8 may not reflect real-world sensitivity, and the open-label design allows for sample size adjustments if deviations arise—introducing potential variability in trial interpretation. Even if Cohort 8 succeeds, securing FDA concurrence to resume non-ambulatory dosing is not guaranteed, as the agency may require additional safety data or impose restrictive conditions given the history of acute serious liver injury and fatal acute liver failure associated with Alevitus, which carries a boxed warning. Furthermore, the non-ambulatory population represents a smaller, more complex subset of Duchenne patients with higher comorbidities, potentially limiting addressable market size and slowing adoption even if approved. The company's own Phase 4 ENHANCE study, which James Richardson described as 'not part of a broader regulatory strategy,' suggests internal recognition that real-world evidence alone may not suffice for regulatory approval, adding uncertainty to the timeline and likelihood of successfully reopening this indication. Without a clear, near-term path to non-ambulatory access, Sarepta misses a meaningful growth lever, leaving growth overly dependent on the slower, education-driven recovery in the ambulatory population.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password